Investor Presentaiton

Investor Presentation First six months of 2018 Slide 70 The GLP-1 segment accounts for 3% of total diabetes care market value in Region AAMEO GLP-1 value in DKK Region AAMEO GLP-1 market VictozaⓇ exenatide VictozaⓇ value market share in Region AAMEO VictozaⓇ exenatide ▪dulaglutide lixisenatide dulaglutide Share of total lixisenatide diabetes care GLP-1 value market share billion market 0.6 3% 100% 0.5 CAGR value¹: 24.0% 80% 0.4 - 2% 60% 0.3 40% 0.2 1% 20% 0.1 0.0 0% 0% May 2013 May 2018 May 2013 1 CAGR for 5-year period AAMEO: Africa, Asia, the Middle East and Oceania Source: IQVIA monthly MAT May, 2018 value figures (DKK) changing diabetes Source: IQVIA monthly MAT May, 2018 value figures (DKK) .46% 33% -20% 1% May 2018 novo nordisk

View entire presentation